From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Deltex Medical – argues “a key opportunity”… but how’s the balance sheet now?

By Steve Moore | Tuesday 11 January 2022

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

Haemodynamic monitoring technologies group Deltex Medical (DEMG) has made a “Pre-close statement”, noting that despite pandemic disruptions for the whole of the year this time, “revenues for the year ended 31 December 2021 were £2.3 million (2020: £2.4 million)” and belief that the backlog in elective surgery “represents a key opportunity for Deltex Medical as the group’s TrueVue Doppler technology can be used to help minimise patient length of stay (and associated costs) following elective surgery and hence increase capacity for hospitals”. With also a ‘next generation’ TrueVue monitor due for release later this year, why a current share price fall to 1.25p?…

You must be a registered member to read this story
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was



More house prices comedy

Monday »


Rumours of two placings FWIW